Study of Enterra Programming with Nocturnal Cycling in Gastroparetics
Enterra Medical, Inc. · NCT05980455
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–70 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Not applicable
- Target enrollment
- 50
- US sites recruiting
- 2
- Study start
- July 10, 2023
- Record last updated
- November 15, 2024
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this research study is to evaluate if different Enterra® device programming methods active during sleeping hours can maintain gastroparesis-related symptom relief and quality of life measures.
Participants in this study with existing Enterra® devices will be randomly assigned to one of three programming methods that will be active during sleep. Participants will answer daily questions about their gastroparesis symptoms on an application with their phone/tablet. Participants will answer quality of life questionnaires about their gastroparesis symptoms at study visits.
Participants will be involved in the study for up to six months after treatment assignment.
Programming parameters in the study are within currently approved labeling.
Being studied: Enterra® Therapy System
Conditions: Gastroparesis; Gastroparesis Nondiabetic; Gastroparesis Due to Diabetes Mellitus
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
In order to be eligible to participate in this study, a participant must meet all of the following criteria:
- Completed informed consent process with signed and dated informed consent form;
- Stated willingness to comply with all study procedures and availability for the duration of the study;
- Male or female, aged ≥18 or ≤70 at time of informed consent;
- Currently implanted with the Enterra® Therapy System (Enterra® II 37800 neurostimulator);
- High GES output defined as remaining pulse generator expected life of > 9 months from enrollment and less than 4 years from the time of implant;
- Stable gastroparesis symptoms, in the opinion of the investigator;
- On stable medical therapy for gastroparesis symptoms;
- On stable supplemental nutritional support during the month prior to enrollment;
- English language comprehension to complete study-required assessments;
- Reliable access to internet-connected smart device(s) to complete study-required assessments.
A participant who meets any of the following criteria will be excluded from participation in this study:
- Post-surgical gastroparesis (e.g., fundoplication, Bilroth I or II) or other active stomach or gastrointestinal diseases disorders which could explain symptoms in the opinion of the investigator;
- Subjects, in the opinion of the investigator, with profound nausea and/or vomiting at night;
- Subjects, in the opinion of the investigator, with profound gastroparesis symptoms upon waking in the morning;
- Subjects without a regular and defined sleep schedule;
- Pregnancy, or subject that intends to become pregnant during participation in the study;
- Chemical dependency;
- Enterra lead impedance measurements ≥ 700 Ohms at screening visit;
- Life expectancy \< 1 year from conditions other than GI diseases;
- Subjects with an underlying disease leading to follow-up by MRI outside of current MR conditional indications;
- Participation in other clinical studies;
- Subjects involved in current or past medical-related litigation;
- Subjects with cognitive impairment or other characteristic that would limit subject's ability to complete study requirements.
Recruiting US locations
University of Louisville
Louisville, KY 40202
Site contact: Abigail Stocker, MD · 5025884600 · abigail.stocker@louisville.edu
MNGI Digestive Health, P.A.
Coon Rapids, MN 55433
Site contact: Roxanne Strehlo
Study contacts (from the official record)
- Timothy McAllister · 855-768-3772 · clinicalresearch@enterramedical.com
- Jason Hamann, PhD · 855-768-3772 · clinicalresearch@enterramedical.com
Similar studies in Kentucky
All diabetes studies in Kentucky →- RecruitingHealthy volunteers
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Cleerly, Inc.
- Location
- Edgewood, KY + 121 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Lexington, KY + 57 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
Boehringer Ingelheim
- Location
- Lexington, KY + 56 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Sanofi
- Location
- Louisville, KY + 33 other US sites
- Eligibility basics
- Ages 1–25